[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment. “Treating very youn...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment. “Treating very youn...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news
Shelby Lynch: TikTok influencer on dispelling disability myths
Shelby Lynch, who has spinal muscular atrophy, answers questions and tackles trolls online. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 9, 2021 Category: Consumer Health News Source Type: news
Take-at-home treatment for spinal muscular atrophy
The oral drug could help children like Melvil born with a condition that causes progressive muscle weakness. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 19, 2021 Category: Consumer Health News Source Type: news
Spinal muscular atrophy treatment
A drug that can improve mobility in children and adults with a rare genetic condition will be available on the NHS. (Source: NHS Networks)
Source: NHS Networks - November 19, 2021 Category: UK Health Source Type: news
Genentech, people with genetic muscle-wasting disease team up for music video
The song, "Spaces," was released Tuesday to highlight the everyday lives of spinal muscular atrophy patients and the disability community in general, people involved in the project said. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 9, 2021 Category: American Health Authors: Ron Leuty Source Type: news
Genentech, people with genetic muscle-wasting disease team up for music video
The song, "Spaces," was released Tuesday to highlight the everyday lives of spinal muscular atrophy patients and the disability community in general, people involved in the project said. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 9, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news
Burden of spinal muscular atrophy high, varies according to disease type and motor function
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
What Is the Life Expectancy of Someone with Spinal Muscular Atrophy?
Title: What Is the Life Expectancy of Someone with Spinal Muscular Atrophy?Category: Diseases and ConditionsCreated: 10/27/2021 12:00:00 AMLast Editorial Review: 10/27/2021 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - October 27, 2021 Category: Pediatrics Source Type: news
Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential benefits of th...
Source: Roche Media News - September 24, 2021 Category: Pharmaceuticals Source Type: news
Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders
Basel, 24 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021. The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to six weeks of age and data supporting the continued clinical investig ation of gene therapy, SRP-9001, in Duchenne muscular dystrophy (DMD).“These new data for Evrysdi may help extend the potential benefits of th...
Source: Roche Investor Update - September 24, 2021 Category: Pharmaceuticals Source Type: news
Egypt: Egypt Launches Initiative for Early Detection of 19 Genetic Diseases in Newborns, Begins Free Treatment of Spinal Muscular Atrophy
[Egypt Online] Minister of Health and Population Hala Zayed announced on Tuesday 3/8/2021 the launch of an initiative for the early detection of genetic disorders and hereditary diseases in newly-born infants under the auspices of President Abdel Fattah El Sisi. (Source: AllAfrica News: Pregnancy and Childbirth)
Source: AllAfrica News: Pregnancy and Childbirth - August 4, 2021 Category: OBGYN Source Type: news
